As diastolic dysfunction and stiffening in MetS patients are associated with increased circulating DPP‐4 levels, we investigated whether the clinically approved DPP‐4 inhibitor linagliptin reduces left ventricular stiffness in MetS‐induced cardiac disease in obese ZSF1 rats.4, 5, 6. Here, DPP4 is linked to heart disorder.